TransCode Therapeutics launches Phase 2a trial of TTX-MC138 in ctDNA-positive colorectal cancer patients

TransCode Therapeutics, Inc.

TransCode Therapeutics, Inc.

RNAZ

0.00
  • TransCode Therapeutics launched a Phase 2a trial of TTX-MC138 in ctDNA-positive colorectal cancer patients following curative-intent therapy.
  • Results have not been presented; the study is expected to generate future data on recurrence-risk reduction in minimal residual disease.
  • Trial targets up to 45 patients with no radiographic disease but persistent or new ctDNA positivity, a marker of residual cancer risk.
  • Study runs with Quantum Leap Healthcare Collaborative on the PRE-I-SPY platform, expanding access to established oncology trial sites.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcode Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605270804PR_NEWS_USPR_____NE68618) on May 27, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.